According to the Zhitong Finance App, Shuanglu Pharmaceutical (002038.SZ) issued an announcement. On November 6, 2023, the company participated in the bidding process for the ninth batch of centralized national drug procurement organized by the Joint Procurement Office (“Joint Procurement Office”). The company's products lenalidomide capsules (Lisheng), voglabose tablets (Lishengtai), and celodoxine capsules (Lishengyu) will win the bid in this centralized procurement. The proposed bid prices are: 286.66 yuan, 4.86 yuan, and 8.63 yuan, respectively.